Effects of Adriamycin-Cytoxan Chemotherapy on Hematological and Electrolyte Parameters Among Breast Cancer Patients

Overview

Journal Front Oncol

Specialty Oncology

Date 2023 May 19

PMID 37205205

Authors

Fikremariam Abiye Tadesse

Abebaye Aragaw Leminie

Affiliations

Soon will be listed here.

Abstract

Background: Adriamycin-Cytoxan (AC) is a common chemotherapy treatment for breast cancer (BC) patients. Its electrolyte and hematological adverse effects have not been addressed adequately.

Objective: This study aimed to assess the effect of AC on hematological and electrolyte parameters among BC patients.

Methods: A hospital-based comparative cross-sectional study design was conducted from March to November 2022. Randomly selected AC-treated (n=100) and untreated (n=100) patients were included. Structured questionnaire and medical records were used to collect sociodemographic data. Anthropometric parameters, hematological indices, and serum electrolytes were measured. Cobas Integra 400and SYSMEX-XT-4000i were used to analyze serum electrolytes and hematological indices respectively. The data were analyzed using SPSS version 25. Independent t-test and chi-square test were used. 0.05 was considered statistically significant.

Results: AC-treated patients' mean total white blood cell (TWBC), neutrophil (NE), lymphocyte (LY), red blood cell (RBC), hemoglobin (Hgb), hematocrit (HCT), and sodium(Na) values were significantly reduced (p<0.05) than patients with no treatment. However, mean eosinophils (EO), platelet (PLT) counts, red cell distribution-width (RDW), potassium (K), and plateletcrit (PCT values were significantly increased (p<0.05).

Conclusion: The majority of blood cells and serum sodium were affected by AC treatment. Incorporating these parameters in the routine analysis and further studies on the detailed mechanism of action of this drug is required.

References

Harris J, Lippman M, Veronesi U, Willett W . Breast cancer (3). N Engl J Med. 1992; 327(7):473-80. DOI: 10.1056/NEJM199208133270706. View

Kuerer H, Newman L, Smith T, Ames F, Hunt K, Dhingra K . Clinical course of breast cancer patients with complete pathologic primary tumor and axillary lymph node response to doxorubicin-based neoadjuvant chemotherapy. J Clin Oncol. 1999; 17(2):460-9. DOI: 10.1200/JCO.1999.17.2.460. View

Rana A, Kaur M, Zonunsanga B, Puri A, Kuka A . Preoperative Peripheral Blood Count in Breast Carcinoma: Predictor of Prognosis or a Routine Test. Int J Breast Cancer. 2015; 2015:964392. PMC: 4677208. DOI: 10.1155/2015/964392. View

Perazella M . Renal vulnerability to drug toxicity. Clin J Am Soc Nephrol. 2009; 4(7):1275-83. DOI: 10.2215/CJN.02050309. View

Clifton K, Barnett C, Martinez A, Karuturi M, Saleem S, Litton J . Severe hyponatremia following cyclophosphamide infusion in breast cancer patients. Breast J. 2018; 24(4):691-692. PMC: 6375476. DOI: 10.1111/tbj.13026. View

Brown T, Sykes D, Allen A . Implications of Breast Cancer Chemotherapy-Induced Inflammation on the Gut, Liver, and Central Nervous System. Biomedicines. 2021; 9(2). PMC: 7917715. DOI: 10.3390/biomedicines9020189. View

Prieto-Callejero B, Rivera F, Fagundo-Rivera J, Romero A, Romero-Martin M, Gomez-Salgado J . Relationship between chemotherapy-induced adverse reactions and health-related quality of life in patients with breast cancer. Medicine (Baltimore). 2020; 99(33):e21695. PMC: 7437745. DOI: 10.1097/MD.0000000000021695. View

Haiman C, Pike M, Bernstein L, Jaque S, Stanczyk F, Afghani A . Ethnic differences in ovulatory function in nulliparous women. Br J Cancer. 2002; 86(3):367-71. PMC: 2375205. DOI: 10.1038/sj.bjc.6600098. View

Lofterod T, Mortensen E, Nalwoga H, Wilsgaard T, Frydenberg H, Risberg T . Impact of pre-diagnostic triglycerides and HDL-cholesterol on breast cancer recurrence and survival by breast cancer subtypes. BMC Cancer. 2018; 18(1):654. PMC: 6003110. DOI: 10.1186/s12885-018-4568-2. View

10.

Peterson L, Hurria A, Feng T, Mohile S, Owusu C, Klepin H . Association between renal function and chemotherapy-related toxicity in older adults with cancer. J Geriatr Oncol. 2016; 8(2):96-101. PMC: 5373948. DOI: 10.1016/j.jgo.2016.10.004. View

11.

Abdul Rasool Hassan B, Binti Mohd Yusoff Z, Hassali M, Othman S, Weiderpass E . Impact of chemotherapy on hypercalcemia in breast and lung cancer patients. Asian Pac J Cancer Prev. 2012; 13(9):4373-8. DOI: 10.7314/apjcp.2012.13.9.4373. View

12.

Baker M, Markman M, Niu J . Cyclophosphamide-induced severe acute hyponatremic encephalopathy in patients with breast cancer: report of two cases. Case Rep Oncol. 2014; 7(2):550-4. PMC: 4164106. DOI: 10.1159/000365832. View

13.

Oronsky B, Caroen S, Oronsky A, Dobalian V, Oronsky N, Lybeck M . Electrolyte disorders with platinum-based chemotherapy: mechanisms, manifestations and management. Cancer Chemother Pharmacol. 2017; 80(5):895-907. PMC: 5676816. DOI: 10.1007/s00280-017-3392-8. View

14.

Ahmed S, Shahid R, Bhatt H, Lee-Ying R, Lim J . Chemotherapy-related thrombocytosis: does it increase the risk of thromboembolism?. Oncology. 2012; 82(6):327-32. DOI: 10.1159/000337235. View

15.

Rampello E, Fricia T, Malaguarnera M . The management of tumor lysis syndrome. Nat Clin Pract Oncol. 2006; 3(8):438-47. DOI: 10.1038/ncponc0581. View

16.

Mansouri E, Jangaran A, Ashtari A . Protective effect of pravastatin on doxorubicin-induced hepatotoxicity. Bratisl Lek Listy. 2017; 118(5):273-277. DOI: 10.4149/BLL_2017_054. View

17.

Paul S, Solanki P, Pratap Shahi U, Srikrishna S . Epidemiological Study on Breast Cancer Associated Risk Factors and Screening Practices among Women in the Holy City of Varanasi, Uttar Pradesh, India. Asian Pac J Cancer Prev. 2016; 16(18):8163-71. DOI: 10.7314/apjcp.2015.16.18.8163. View

18.

McBride A, Westervelt P . Recognizing and managing the expanded risk of tumor lysis syndrome in hematologic and solid malignancies. J Hematol Oncol. 2012; 5:75. PMC: 3544586. DOI: 10.1186/1756-8722-5-75. View

19.

Poncin A, Onesti C, Josse C, Boulet D, Thiry J, Bours V . Immunity and Breast Cancer: Focus on Eosinophils. Biomedicines. 2021; 9(9). PMC: 8470317. DOI: 10.3390/biomedicines9091087. View

20.

Yokoyama C, Sueyoshi Y, Ema M, Mori Y, Takaishi K, Hisatomi H . Induction of oxidative stress by anticancer drugs in the presence and absence of cells. Oncol Lett. 2017; 14(5):6066-6070. PMC: 5661396. DOI: 10.3892/ol.2017.6931. View